NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $25 PT on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)
Aegis Capital Corp. has reiterated a ‘Buy’ rating and $25 price target on the stock of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE). The report follows the unexpected delay of the company’s CTP-543 phase 2a trial for alopecia areata. The delay of one quarter was caused by the tablet being unable to meet release criteria regarding appearance. The analyst noted this delay as insignificant and reiterated the ‘Buy’ rating. For more information visit www.concertpharma.com About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet…







